Surfactant Protein-B Polymorphisms and Mortality in the Acute Respiratory Distress Syndrome*

Critical Care Medicine - United States
doi 10.1097/ccm.0b013e318183f608
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Surfactant Treatment for Acute Respiratory Distress Syndrome

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
1999English

Surfactant Medication for Acute Respiratory Distress Syndrome

Thorax
PulmonaryRespiratory Medicine
1997English

Effect of Recombinant Surfactant Protein C–Based Surfactant on the Acute Respiratory Distress Syndrome

New England Journal of Medicine
Medicine
2004English

Sulforhodamine B and Exogenous Surfactant Effects on Alveolar Surface Tension in Acute Respiratory Distress Syndrome Models

2020English

Surfactant Protein a (SP-A) Is a Prognostic Molecular Biomarker in Acute Respiratory Distress Syndrome

Obshchaya Reanimatologiya
Critical CareIntensive Care Medicine
2013English

Reduced Mortality in Association With the Acute Respiratory Distress Syndrome (ARDS)

Thorax
PulmonaryRespiratory Medicine
1998English

Cytomegalovirus Reactivation and Mortality in Patients With Acute Respiratory Distress Syndrome

Intensive Care Medicine
Critical CareIntensive Care Medicine
2016English

Treatment of Acute Respiratory Distress Syndrome in Secondary Surfactant Deficiency in Neonates

Paediatrica Indonesiana
2007English

Exogenous Natural Surfactant for Treatment of Acute Lung Injury and the Acute Respiratory Distress Syndrome

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy